A New Injectable Biomaterial Heals Damaged Heart Tissue From the Inside Out

The human heart is notoriously bad at healing itself. When a heart attack strikes, blocked blood flow starves cardiac tissue of oxygen, causing muscle cells to die. The body’s emergency response is to patch the damage with rigid scar tissue. While this scarring prevents the heart wall from rupturing in the immediate aftermath, it comes at a steep long-term cost. Scar tissue does not beat or contract like healthy cardiac muscle. Over time, the heart must work harder to pump blood, a strain that frequently leads to congestive heart failure—a debilitating and often fatal condition. In the United States alone, an estimated 785,000 new heart attacks occur each year, leaving a massive population of survivors at risk for progressive heart disease. For decades, cardiologists have searched for a way to interrupt this scarring process and encourage the heart to regenerate healthy muscle instead.[1][2][3]

Now, a team of bioengineers and physicians at the University of California San Diego has developed a breakthrough that could fundamentally change how we treat heart attacks. Led by bioengineering professor Karen Christman, the researchers have engineered a novel biomaterial that can be injected intravenously immediately after a cardiac event. Once in the bloodstream, this material acts like a microscopic repair crew. It actively seeks out the damaged, inflamed tissue in the heart, seals leaky blood vessels, and provides a biological scaffold that encourages the growth of new, healthy cells. Described by Christman as a way to heal tissue "from the inside out," the therapy represents a major leap forward in regenerative medicine, offering a less invasive and highly targeted approach to repairing organs that are otherwise difficult to access.[2][3][4]

The foundation of this new therapy is a substance known as the extracellular matrix (ECM). In healthy tissue, the ECM is the natural, protein-rich scaffolding that surrounds cells, providing them with structural support and biochemical cues. To create their biomaterial, the UC San Diego team harvested cardiac muscle tissue from pigs, stripped away the living cells, and broke down the remaining extracellular matrix into a liquid hydrogel. This hydrogel retains the natural proteins and signaling molecules that tell cardiac cells how to grow and behave. The concept of using ECM hydrogels to repair the heart is not entirely new; Christman’s lab had previously developed a version that successfully completed a Phase 1 human clinical trial in 2019. However, that earlier iteration had a significant clinical limitation.[1][2]

The original hydrogel was thick and had to be delivered directly into the damaged heart muscle using a catheter. Because the heart tissue is incredibly fragile immediately following a heart attack, doctors cannot safely insert a needle into the muscle wall without risking a fatal rupture. As a result, the original gel could only be administered a week or more after the initial event. By that time, the damaging inflammatory cascade is already well underway, and scar tissue has begun to form. To truly prevent heart failure, cardiologists needed a treatment that could be given in the emergency room, within hours of the attack. They needed a material that could travel through the bloodstream and find the damage on its own.[2][3]

Transforming the thick hydrogel into an intravenous therapy required a feat of nano-engineering. The primary obstacle was the size of the particles within the original gel; they were simply too large to navigate the circulatory system and target the microscopic leaks in damaged blood vessels. Martin Spang, a researcher in Christman’s lab, solved this problem by processing the liquid precursor of the hydrogel in a high-speed centrifuge. This spinning process separated the heavier, larger particles from the mixture, allowing the team to isolate only the nano-sized fragments. The refined liquid was then put through dialysis, sterile filtering, and freeze-drying. The resulting powder, when mixed with sterile water, forms a potent, nanoscale biomaterial perfectly suited for intravenous injection.[1][2]

Once injected into a vein, the nanoscale biomaterial circulates throughout the body, but it does not accumulate in healthy tissue. Instead, it exploits a biological phenomenon unique to injury sites. When tissue is damaged—such as the heart muscle during an attack—the local blood vessels become inflamed and "leaky." The endothelial cells that line the inside of the vessels pull apart, creating microscopic gaps. The UC San Diego biomaterial is specifically sized to slip into these gaps. As it binds to the leaky microvasculature, it effectively seals the vessels, halting the inflammatory cells that would otherwise flood the tissue and trigger the formation of scar tissue.[1][2][4]

The biomaterial's work is fast and highly localized. Once it binds to the damaged blood vessels, it forms a temporary, supportive scaffold right at the site of the injury. This scaffold provides a welcoming environment for the body's own stem cells and repair mechanisms to take hold, jumpstarting the regeneration of healthy tissue rather than rigid scars. Remarkably, the biomaterial itself does not linger in the body. It is largely degraded and cleared away within about three days. Yet, in that short window, it fundamentally alters the trajectory of the healing process, shifting the heart's response from panic and scarring to structured repair.[1][2][5]

The efficacy of this intravenous approach has been rigorously tested in both rodent and large animal models. In pigs, whose hearts closely resemble human hearts in size and function, the biomaterial successfully reduced inflammation and improved tissue repair following an induced heart attack. Because the material is delivered via the bloodstream, it spreads evenly throughout the damaged areas, reaching microscopic zones of injury that a localized catheter injection might miss. For interventional cardiologists, this systemic delivery method is a game-changer. It means a patient arriving at the hospital with a heart attack could potentially receive a regenerative infusion alongside standard clot-busting drugs, protecting the heart muscle from the very first day.[1][2][3]

While the immediate focus is on cardiac care, the implications of this "inside out" healing mechanism extend far beyond the heart. Inflammation and leaky blood vessels are hallmarks of tissue damage across the entire body. Recognizing this, the UC San Diego researchers tested their nanoscale biomaterial on other difficult-to-treat conditions in rodent models. They found that the intravenous injection showed significant promise in treating traumatic brain injury (TBI) and pulmonary arterial hypertension. In the case of TBI, accessing the damaged brain tissue is notoriously difficult and invasive. A therapy that can simply be injected into a vein and trusted to find the inflamed neural blood vessels on its own could revolutionize neurocritical care.[1][2][6]

The transition from a laboratory breakthrough to a standard medical treatment is a long and heavily regulated process, but the UC San Diego team is moving aggressively toward the clinic. Christman and Ventrix Bio, Inc., a startup she co-founded, are currently preparing to seek authorization from the U.S. Food and Drug Administration to begin human trials. If the regulatory process proceeds smoothly, early-stage safety and efficacy studies in human patients could commence within the next one to two years. For the hundreds of thousands of patients who suffer heart attacks annually, the prospect of an off-the-shelf, intravenous regenerative therapy offers a profound new source of hope.[2][3][4]

The development of this biomaterial also highlights a broader shift in the field of regenerative medicine. For years, scientists focused heavily on stem cell therapies—attempting to inject living cells into damaged organs with the hope that they would take root and multiply. However, stem cell therapies have faced significant hurdles, including poor cell survival rates and the risk of immune rejection. The UC San Diego approach sidesteps these issues entirely by using an acellular material. Because the biomaterial is stripped of living cells, it does not trigger an adverse immune response, making it a universal, off-the-shelf treatment that does not need to be matched to individual patients.[1][2][4]

As researchers prepare for the next phase of clinical trials, the medical community is watching closely. If successful in humans, this nanoscale hydrogel could become a standard protocol in emergency rooms worldwide, administered as routinely as aspirin or blood thinners during a cardiac event. By addressing the root cause of post-heart attack deterioration—the unchecked inflammation and subsequent scarring—this technology promises to do more than just save lives in the short term. It holds the potential to preserve the quality of life for survivors, keeping their hearts strong and resilient for decades to come.[2][3][5][6]